Show simple item record

dc.contributor.authorFurst, Daniel E.
dc.contributor.authorPangan, Aileen L.
dc.contributor.authorHarrold, Leslie R.
dc.contributor.authorChang, Hong
dc.contributor.authorReed, George W.
dc.contributor.authorKremer, Joel
dc.contributor.authorGreenberg, Jeffrey D.
dc.date2022-08-11T08:09:23.000
dc.date.accessioned2022-08-23T16:28:57Z
dc.date.available2022-08-23T16:28:57Z
dc.date.issued2011-06-22
dc.date.submitted2012-01-30
dc.identifier.citationArthritis Care Res (Hoboken). 2011 Jun;63(6):856-64. doi: 10.1002/acr.20452. <a href="http://dx.doi.org/10.1002/acr.20452">Link to article on publisher's site</a>
dc.identifier.issn2151-464X (Linking)
dc.identifier.doi10.1002/acr.20452
dc.identifier.pmid21337725
dc.identifier.urihttp://hdl.handle.net/20.500.14038/37135
dc.description.abstractOBJECTIVE: To examine whether disease duration is an independent predictor of achieving remission in rheumatoid arthritis (RA) patients initiating therapy. METHODS: RA patients in the Consortium of Rheumatology Researchers of North America registry newly prescribed a nonbiologic disease-modifying antirheumatic drug (DMARD) or anti--tumor necrosis factor (anti-TNF) with at least one followup visit were identified. RESULTS: Among the 1,646 nonbiologic DMARD initiators, CDAI remission occurred in 21.3% of those with ≤5 years of disease duration, 19.6% with 6-10 years, and 13.5% with greater than or equal to 11 years (P < 0.001); sustained remission occurred in 10.2%, 8.8%, and 2.5%, respectively (P < 0.001). Results were similar among the 3,179 anti-TNF initiators (CDAI remission in 22.3%, 17.7%, and 12.8%, respectively [P < 0.001]; CDAI sustained remission in 9.7%, 9.5%, and 4.2%, respectively [P < 0.001]). DAS28 results were similar in both groups. In adjusted analyses, an increase of disease duration by 5 years was associated with a reduced likelihood of CDAI remission in nonbiologic DMARD (odds ratio [OR] 0.91, 95% confidence interval [95% CI] 0.83-0.99) and anti-TNF initiators (OR 0.88, 95% CI 0.83-0.94). A similar result was seen for sustained remission using the CDAI (nonbiologic DMARD: OR 0.61, 95% CI 0.48-0.76; anti-TNF: OR 0.85, 95% CI 0.75-0.97). CONCLUSION: Earlier treatment was associated with a greater likelihood of remission.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=21337725&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1002/acr.20452
dc.subjectAdult
dc.subjectAged
dc.subjectAntirheumatic Agents
dc.subjectArthritis, Rheumatoid
dc.subjectCohort Studies
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNorth America
dc.subjectProspective Studies
dc.subject*Registries
dc.subjectRemission Induction
dc.subjectRheumatology
dc.subjectTime Factors
dc.subjectTumor Necrosis Factor-alpha
dc.subjectHealth Services Research
dc.subjectMusculoskeletal Diseases
dc.subjectPrimary Care
dc.titleGreater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry
dc.typeJournal Article
dc.source.journaltitleArthritis care and research
dc.source.volume63
dc.source.issue6
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/meyers_pp/512
dc.identifier.contextkey2479522
html.description.abstract<p>OBJECTIVE: To examine whether disease duration is an independent predictor of achieving remission in rheumatoid arthritis (RA) patients initiating therapy.</p> <p>METHODS: RA patients in the Consortium of Rheumatology Researchers of North America registry newly prescribed a nonbiologic disease-modifying antirheumatic drug (DMARD) or anti--tumor necrosis factor (anti-TNF) with at least one followup visit were identified.</p> <p>RESULTS: Among the 1,646 nonbiologic DMARD initiators, CDAI remission occurred in 21.3% of those with ≤5 years of disease duration, 19.6% with 6-10 years, and 13.5% with greater than or equal to 11 years (P < 0.001); sustained remission occurred in 10.2%, 8.8%, and 2.5%, respectively (P < 0.001). Results were similar among the 3,179 anti-TNF initiators (CDAI remission in 22.3%, 17.7%, and 12.8%, respectively [P < 0.001]; CDAI sustained remission in 9.7%, 9.5%, and 4.2%, respectively [P < 0.001]). DAS28 results were similar in both groups. In adjusted analyses, an increase of disease duration by 5 years was associated with a reduced likelihood of CDAI remission in nonbiologic DMARD (odds ratio [OR] 0.91, 95% confidence interval [95% CI] 0.83-0.99) and anti-TNF initiators (OR 0.88, 95% CI 0.83-0.94). A similar result was seen for sustained remission using the CDAI (nonbiologic DMARD: OR 0.61, 95% CI 0.48-0.76; anti-TNF: OR 0.85, 95% CI 0.75-0.97).</p> <p>CONCLUSION: Earlier treatment was associated with a greater likelihood of remission.</p>
dc.identifier.submissionpathmeyers_pp/512
dc.contributor.departmentDepartment of Medicine, Division of Preventive and Behavorial Medicine
dc.contributor.departmentDepartment of Medicine, Division of Rheumatology
dc.contributor.departmentMeyers Primary Care Institute
dc.source.pages856-64


This item appears in the following Collection(s)

Show simple item record